This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marttunen, M. B. Articles by Ylikorkala, O. Search for Related Content PubMed PubMed Citation Articles by Marttunen, M. B. Articles by Ylikorkala, O.

Comparison of Effects of Tamoxifen and Toremifene on Bone Biochemistry and Bone Mineral Density in Postmenopausal Breast Cancer Patients

Departments of Obstetrics and Gynecology (M.B.M., A.T., O.Y.) and Oncology (P.H.), Helsinki University Central Hospital, FIN-00290 Helsinki, Finland

Address all correspondence and requests for reprints to: Merja B. Marttunen, M.D., Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Haartmaninkatu 2, FIN-00290 Helsinki, Finland.

Abstract

Antiestrogens are used in the treatment, and sometimes even in the prophylaxis, of breast cancer. Tamoxifen is the most commonly used antiestrogen, but toremifene is gaining in popularity. We compared here the effects of tamoxifen and toremifene on bone metabolism and density in 30 postmenopausal patients with breast cancer, who were randomized to receive tamoxifen (20 mg/day, n = 16) or toremifene (40 mg/day, n = 14) for 1 yr. Biochemical markers of bone resorption [urinary hydroxyproline, serum cross-linked carboxyterminal telopeptide of type I collagen, urinary cross-linked aminoterminal telopeptide of type I collagen (NTx)] and bone formation [serum bone-specific alkaline phosphatase, osteocalcin, and aminoterminal and carboxyterminal propeptide of type I procollagen] were assessed before treatment and at 6 and 12 months of the antiestrogen regimen. Bone mineral density (BMD) in the lumbar spine and proximal femur (neck, trochanter, and Ward’s triangle) was measured using dual-energy x-ray absorptiometry before treatment and at 12 months of treatment.

Urinary NTx decreased after 6 months’ use of tamoxifen (mean fall: 33%) and of toremifene (mean fall: 16%). Use of tamoxifen was associated with a significant decrease in osteocalcin (mean fall: 25%) and aminoterminal propeptide of type I procollagen (mean fall: 22%), whereas toremifene failed to influence these markers. Tamoxifen increased BMD, on average, by 2% in the lumbar spine, 1% in the femoral neck, and 5% in Ward’s triangle. Toremifene failed to increase BMD at any site measured, and in contrast, a slight trend toward a fall (-0.3 to -0.9%) in BMD was seen in patients treated with toremifene. Falls in urinary NTx, from baseline to 6 months, correlated significantly with changes in the lumbar spine BMD (r = -0.57, P = 0.0002) in the whole patient series.

We conclude that tamoxifen (20 mg/day) increases BMD in postmenopausal breast cancer patients, whereas toremifene (40 mg/day) merely prevents the increasing age-associated fall in BMD. More prolonged studies on bone metabolism, comparing these two antiestrogens, are needed; but even now, clinicians should be aware of these differences between tamoxifen and toremifene.

This article has been cited by other articles:

				R. Eastell, J. E. Adams, R. E. Coleman, A. Howell, R. A. Hannon, J. Cuzick, J. R. Mackey, M. W. Beckmann, and G. Clack Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230 J. Clin. Oncol., March 1, 2008; 26(7): 1051 - 1057. [Abstract] [Full Text] [PDF]

				E. Yaman, M. Benekli, U. Coskun, B. Ozturk, A. O. Kaya, R. Yildiz, and S. Buyukberber Reply to the article "Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171) Ann. Onc., February 1, 2008; 19(2): 397 - 398. [Full Text] [PDF]

				A. Howell Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 689 - 706. [Abstract] [Full Text] [PDF]

				A. U Buzdar and J. F. Robertson Fulvestrant: Pharmacologic Profile Versus Existing Endocrine Agents for the Treatment of Breast Cancer Ann. Pharmacother., September 1, 2006; 40(9): 1572 - 1582. [Abstract] [Full Text] [PDF]

				L. B. Michaud and S. Goodin Cancer-treatment-induced bone loss, part 1 Am. J. Health Syst. Pharm., March 1, 2006; 63(5): 419 - 430. [Abstract] [Full Text] [PDF]

				L. Vehmanen, I. Elomaa, C. Blomqvist, and T. Saarto Tamoxifen Treatment After Adjuvant Chemotherapy Has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual Status J. Clin. Oncol., February 1, 2006; 24(4): 675 - 680. [Abstract] [Full Text] [PDF]

				S. Banerjee, I. E. Smith, L. Folkerd, J. Iqbal, P. Barker, M. Dowsett, and On behalf of the IMPACT trialists Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial Ann. Onc., October 1, 2005; 16(10): 1632 - 1638. [Abstract] [Full Text] [PDF]

				M. J. Perry, S. Gujra, T. Whitworth, and J. H. Tobias Tamoxifen Stimulates Cancellous Bone Formation in Long Bones of Female Mice Endocrinology, March 1, 2005; 146(3): 1060 - 1065. [Abstract] [Full Text] [PDF]

				K. L Jones and A. U Buzdar A review of adjuvant hormonal therapy in breast cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 391 - 406. [Abstract] [Full Text] [PDF]

				E. Nikander, M. Metsa-Heikkila, O. Ylikorkala, and A. Tiitinen Effects of Phytoestrogens on Bone Turnover in Postmenopausal Women with a History of Breast Cancer J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1207 - 1212. [Abstract] [Full Text] [PDF]

				B. L. Riggs and L. C. Hartmann Selective Estrogen-Receptor Modulators -- Mechanisms of Action and Application to Clinical Practice N. Engl. J. Med., February 13, 2003; 348(7): 618 - 629. [Full Text] [PDF]

				C. Harper-Wynne, G. Ross, N. Sacks, J. Salter, N. Nasiri, J. Iqbal, R. A'Hern, and M. Dowsett Effects of the Aromatase Inhibitor Letrozole on Normal Breast Epithelial Cell Proliferation and Metabolic Indices in Postmenopausal Women: A Pilot Study for Breast Cancer Prevention Cancer Epidemiol. Biomarkers Prev., July 1, 2002; 11(7): 614 - 621. [Abstract] [Full Text] [PDF]

				A. C. WOLFF and N. E. DAVIDSON Use of SERMs for the Adjuvant Therapy of Early-Stage Breast Cancer Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 80 - 88. [Abstract] [Full Text] [PDF]

				D. B. Muchmore Raloxifene: A Selective Estrogen Receptor Modulator (SERM) with Multiple Target System Effects Oncologist, October 1, 2000; 5(5): 388 - 392. [Abstract] [Full Text]

				C. K. Osborne and S. A. W. Fuqua Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use J. Clin. Oncol., September 17, 2000; 18(17): 3172 - 3186. [Abstract] [Full Text] [PDF]

				J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]

				L. louffe Jr. Selective Estrogen Receptor Modulators (SERMs) in Clinical Practice Reproductive Sciences, January 1, 2000; 7(1_suppl): S38 - S46. [Abstract] [PDF]

				R. T. Chlebowski, D. E. Collyar, M. R. Somerfield, and D. G. Pfister American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene J. Clin. Oncol., June 1, 1999; 17(6): 1939 - 1939. [Abstract] [Full Text] [PDF]